1. Home
  2. OVID vs ASMB Comparison

OVID vs ASMB Comparison

Compare OVID & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

OVID

Ovid Therapeutics Inc.

N/A

Current Price

$2.56

Market Cap

503.9M

Sector

Health Care

ML Signal

N/A

Logo Assembly Biosciences Inc.

ASMB

Assembly Biosciences Inc.

N/A

Current Price

$19.95

Market Cap

512.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
OVID
ASMB
Founded
2014
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
503.9M
512.1M
IPO Year
2017
2010

Fundamental Metrics

Financial Performance
Metric
OVID
ASMB
Price
$2.56
$19.95
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
13
5
Target Price
$6.40
★ $51.20
AVG Volume (30 Days)
★ 2.4M
201.9K
Earning Date
11-10-2026
11-24-2026
Dividend Yield
N/A
N/A
EPS Growth
3.90
★ 91.78
EPS
★ N/A
N/A
Revenue
★ $7,252,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 1181.27
N/A
52 Week Low
$1.18
$19.20
52 Week High
$3.11
$39.71

Technical Indicators

Market Signals
Indicator
OVID
ASMB
Relative Strength Index (RSI) 50.37 42.68
Support Level $2.12 $19.25
Resistance Level $2.67 $21.65
Average True Range (ATR) 0.24 1.16
MACD 0.03 0.37
Stochastic Oscillator 44.95 26.65

Price Performance

Historical Comparison
OVID
ASMB

About OVID Ovid Therapeutics Inc.

Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.

About ASMB Assembly Biosciences Inc.

Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.

Share on Social Networks: